Cardiovascular and hematologic effects produced by chronic treatment with etoricoxib in normotensive rats

Author:

Baracho Nilo César do Vale1,Guizelli Guilherme Pedrosa1,Carmello Beatriz Leone1,Sanches Danielle de Souza1,Silva Felipe Moraes Costa1,Reis José Marcos dos1,Brito Jarbas de1

Affiliation:

1. FMIt, Brazil

Abstract

PURPOSE: Evaluate the cardiovascular and hematological effects produced by chronic treatment with two dosis of etoricoxib in Wistar normotensive rats. METHODS: Thirty rats have been used and divided into one control group and two etoricoxib (10mg/kg and 30mg/kg) treatments groups for 60 days. The mean arterial pressure (MAP) was taken during the whole experimental period and at the end of this period, under anesthesia blood samples were taken, and further the withdrawn of the aorta, heart, brain, liver, and kidneys for the anatomopathologic study. RESULTS: The treatment with etoricoxib (30mg/Kg) produced a significant increase of the MAP from the 28th day of the experiment and from the platelets when compared to the control group and to the group treated with 10mg/Kg, besides producing a highly significant difference in hematocrit and in the red blood cells in relation to the control group. On the other hand the treatment with etoricoxib has not caused histopathological changes when compared to the control. CONCLUSION: These data show that the chronic treatment with etoricoxib leads to increase of the MAP, and to important hematological changes which seem to be associated to the hemoconcentration although not producing anatomopathological significant changes.

Publisher

FapUNIFESP (SciELO)

Subject

Surgery

Reference17 articles.

1. Regulation of inflammatory vascular damage;Lentsch AB;J Pathol.,2000

2. Stress hormones, Th1/ Th2 patterns, pro/antiinflammatory cytokines and susceptibility to disease;Elenkov IJ;Trends Endocrinol Metabol.,1999

3. Eventos cardiovasculares: um efeito de classe dos inibidores de COX-2;Araujo LF;Arq Bras Cardiol.,2005

4. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers;Rodrigues AD;Drug Metab Dispos.,2003

5. Tienen futuro los inhibidores de la ciclooxigenasa-2?;Bannwarth B;Drug Safety.,2005

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3